🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06547710
Recruiting Observational

Primary Tumor Resection for M1a Stage Lung Cancer

NCT06547710 · tracked via the Priya Life Science China tracker
Sponsor
Fudan University
Phase
Observational
Started
2024-04-01
Last updated
2026-07-08

Condition(s) studied

Lung Cancer MetastaticSurgical Resection

Study summary

This is a clinical trial from Eastern Cooperative Thoracic Oncology Project (ECTOP), numbered as ECTOP-1023. This study aims to explore the safety and efficacy of primary lesion resection in the treatment of M1a stage lung cancer with pleural dissemination found during surgery, and to more accurately evaluate whether primary lesion resection can improve the OS and quality of life of the corresponding patients.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: 1. Volunteer to participate in clinical research, willing to follow and able to complete all trial procedures; 2. Aged 18-80 years (including critical values) when signing the informed consent form; 3. ECOG score 0 or 1; 4. No previous lung cancer surgery; 5. Intraoperative or postoperative pathological confirmation of M1a stage lung cancer; 6. Occult pleural metastasis found during surgery; 7. First-time treatment and no radiotherapy or chemotherapy. Exclusion Criteria: 1. The lesion cannot be completely removed surgically; 2. Cytological or histological pathology confirms other lung malignancies other than lung cancer; 3. Patients who have undergone lung cancer surgery before; 4. Patients who have received radiotherapy or chemotherapy and are not treatment-naive patients.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Fudan University Cancer Center Shanghai Shanghai Municipality Recruiting

More Fudan University trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06547710 on ClinicalTrials.gov ↗ ← All trials in China